ENGLEWOOD, Colo., Sept. 14, 2020 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the advancement of
immunology-based therapies for prevalent inflammatory conditions,
today announced that Michael Roshon,
MD, PhD, Chief of Staff at Penrose-St. Francis
Hospital in Colorado Springs, Colorado, who served as Principal Investigator of the just completed
Phase I trial of intravenous Ampion™ for treatment of COVID-19
patients, and David Bar-Or, MD, founder of Ampio Pharmaceuticals,
were interviewed about those clinical results on a Colorado affiliate FOX news
segment titled, "Colorado Drug shows promise against
COVID-19", which can be viewed in its entirety at:
https://kdvr.com/video/colorado-drug-shows-promise-against-covid-19/5844056/
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment
options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2032, and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act
("BPCIA").
Forward-Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampion-phase-i-covid-19-patient-trial-results-featured-on-fox-news-video-301130079.html
SOURCE Ampio Pharmaceuticals, Inc.